- Home
- KRC vs ADMA Comparison
KRC vs ADMA Comparison
Compare KRC & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | ADMA |
|---|---|---|
| Founded | 1947 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.1B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | KRC | ADMA |
|---|---|---|
| Price | $40.44 | $19.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $41.58 | $28.50 |
| AVG Volume (30 Days) | 1.2M | ★ 3.3M |
| Earning Date | 10-27-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | 62.23 | ★ 205.35 |
| EPS | ★ 2.71 | 0.86 |
| Revenue | ★ $1,126,859,000.00 | $488,559,000.00 |
| Revenue This Year | N/A | $22.19 |
| Revenue Next Year | $4.41 | $24.33 |
| P/E Ratio | ★ $14.92 | $22.65 |
| Revenue Growth | 0.77 | ★ 27.63 |
| 52 Week Low | $27.07 | $13.50 |
| 52 Week High | $45.03 | $25.67 |
Technical Indicators
Market Signals| Indicator | KRC | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.31 | 68.60 |
| Support Level | $40.10 | $18.73 |
| Resistance Level | $41.56 | $20.22 |
| Average True Range (ATR) | 1.14 | 0.77 |
| MACD | -0.18 | 0.19 |
| Stochastic Oscillator | 15.46 | 83.13 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 17 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.